Arrowhead Pharmaceuticals Reports Significant Reduction in Pancreatitis Rates via Plozasiran
Arrowhead Pharmaceuticals (ARWR) announced positive clinical data from a pooled analysis of two late-stage studies for its drug, plozasiran. The results demonstrated that the treatment reduced the incidence of acute pancreatitis by 78% compared to a placebo group. In addition to the pancreatitis findings, the company shared early-stage results regarding an experimental cholesterol-lowering treatment. These developments represent significant progress in Arrowhead's RNAi therapeutic pipeline, potentially addressing critical unmet needs in metabolic and inflammatory diseases.
Tickers: $ARWR
Topics: clinical trial results drug efficacy pancreatitis treatment